The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Mark J. Ratain and Walter M. Stadler.
Connection Strength

3.634
  1. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6.
    View in: PubMed
    Score: 0.273
  2. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
    View in: PubMed
    Score: 0.265
  3. Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
    View in: PubMed
    Score: 0.240
  4. Clinical trial designs for cytostatic agents. J Clin Oncol. 2001 Jun 15; 19(12):3154-5.
    View in: PubMed
    Score: 0.202
  5. The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check. JAMA Oncol. 2021 06 01; 7(6):827-828.
    View in: PubMed
    Score: 0.201
  6. Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16.
    View in: PubMed
    Score: 0.183
  7. Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. J Clin Oncol. 2018 10 20; 36(30):3064-3065.
    View in: PubMed
    Score: 0.166
  8. Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061.
    View in: PubMed
    Score: 0.166
  9. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
    View in: PubMed
    Score: 0.161
  10. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.153
  11. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
    View in: PubMed
    Score: 0.105
  12. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
    View in: PubMed
    Score: 0.101
  13. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.099
  14. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
    View in: PubMed
    Score: 0.096
  15. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.089
  16. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
    View in: PubMed
    Score: 0.086
  17. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.084
  18. Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11.
    View in: PubMed
    Score: 0.079
  19. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
    View in: PubMed
    Score: 0.078
  20. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov; 31(6):783-5.
    View in: PubMed
    Score: 0.072
  21. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
    View in: PubMed
    Score: 0.071
  22. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4544.
    View in: PubMed
    Score: 0.066
  23. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65.
    View in: PubMed
    Score: 0.066
  24. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84.
    View in: PubMed
    Score: 0.056
  25. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
    View in: PubMed
    Score: 0.051
  26. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
    View in: PubMed
    Score: 0.050
  27. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94.
    View in: PubMed
    Score: 0.046
  28. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
    View in: PubMed
    Score: 0.043
  29. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38.
    View in: PubMed
    Score: 0.043
  30. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.041
  31. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
    View in: PubMed
    Score: 0.038
  32. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
    View in: PubMed
    Score: 0.028
  33. Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design. Am Stat. 2012; 66(3):155-162.
    View in: PubMed
    Score: 0.026
  34. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
    View in: PubMed
    Score: 0.023
  35. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
    View in: PubMed
    Score: 0.016
  36. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
    View in: PubMed
    Score: 0.015
  37. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
    View in: PubMed
    Score: 0.014
  38. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5.
    View in: PubMed
    Score: 0.012
  39. Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
    View in: PubMed
    Score: 0.010
  40. Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer. 1998 Apr 01; 82(7):1352-8.
    View in: PubMed
    Score: 0.010
  41. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.